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Background: The cyclin-dependent kinase inhibitor p27Kip1 functions during normal cerebellar development and
has demonstrated tumor suppressor functions in mouse models of medulloblastoma. Because P27 loss is associated
with increased proliferation, we assessed whether P27 absence in surgical medulloblastoma specimens correlated
with response to therapy in pediatric patients enrolled in two large studies. Additionally, we examined the
functional consequence of p27Kip1 loss in the SmoA1 medulloblastoma model to distinguish whether p27Kip1
reduces tumor initiation or slows tumor progression.
Findings: Analysis of 87 well-characterized patient samples identified a threshold of P27 staining at which
significant P27 loss correlated with poor patient outcome. The same criteria, applied to a second test set of tissues
from 141 patients showed no difference in survival between patients with minimal P27 staining and others,
suggesting that P27 levels alone are not a sufficient prognostic indicator for identifying standard-risk patients that
may fail standard therapy. These findings were in contrast to prior experiments completed using a mouse
medulloblastoma model. Analysis of cerebellar tumor incidence in compound mutant mice carrying the activated
Smoothened (SmoA1) allele that were heterozygous or nullizygous for p27Kip1 revealed that p27Kip1 loss did not alter
the frequency of tumor initiation. Tumors haploinsufficient or nullizygous for p27Kip1 were, however, more invasive
and displayed a higher proliferative index, suggesting p27Kip1 loss may contribute to SmoA1 medulloblastoma
progression.
Conclusions: These studies revealed P27 loss affects medulloblastoma progression rather than initiation and that
this putative biomarker should not be used for stratifying children with medulloblastoma to risk-based therapeutic
regimens.
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Approximately 20% of medulloblastoma patients classi-
fied as standard risk fail therapy and succumb to their
disease [1]. Current prognostic criteria stratify patients
into standard- or high-risk groups based upon age, the
extent of surgical resection and the presence or absence
of disseminated disease [2]. The intensity of radio- and* Correspondence: jolson@fhcrc.org
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reproduction in any medium, provided the orchemotherapy are determined by risk group, although
significant impairments induced by current strategies are
well established, particularly in younger patients [2,3].
Because of these devastating toxicities, efforts are under-
way to reduce therapy intensity for standard risk pa-
tients. As the pediatric neuro-oncology community
begins to de-escalate standard risk therapy, it conse-
quently becomes critically important to identify molecu-
lar markers that recognize children likely to fail therapy
that would benefit from stratification to more intensive
therapeutic regimens.
Studies in various mouse models have demonstrated
that loss of a single p27Kip1 [GenBank: NM_009875]
allele increases tumor formation, suggesting p27Kip1’sLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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a dosage-dependent manner [4]. In the SmoA1 mouse
medulloblastoma model, loss of P27 resulted in early
death compared to counterparts with wildtype P27 levels
[5]. While this work showed that P27 has tumor sup-
pressive function in medulloblastoma, it remained to be
determined whether loss of P27 caused an increase in
tumor initiation or progression. This is an important dis-
tinction because molecules involved in tumor initiation
are rarely good prognostic indicators, whereas a subset
of molecules involved in tumor progression reliably pre-
dict response to therapy.
While p27Kip1mutations are generally rare, P27 abun-
dance has provided a reliable prognostic marker for can-
cer progression in a subset of human cancers, such as
breast, colon and prostate [6,7]. The prognostic value of
P27 expression in human medulloblastoma is currently
unknown. Previous studies using 14 human medullo-
blastoma samples found low or absent P27 expression in
highly proliferative and undifferentiated tumor regions
[8,9], but the sample size was too small to assess prog-
nostic value.
This study first addresses the unanswered question re-
garding P27’s role in tumor initiation versus progression
in experiments conducted in a genetically engineered
mouse medulloblastoma model. This study additionally
assesses P27’s potential as a prognostic indicator in chil-
dren with medulloblastoma. The study evaluates
whether clinical outcomes improve for children with
high P27 first in a retrospective clinical trial cohort
(training data set) and then in a larger clinical trial co-
hort (test data set).
Methods
Compound mutant mice
SmoA1 mice were crossed with heterozygous p27wt/-
mice to produce compound mutant (SmoA1, p27wt/- and
SmoA1, p27−/−) mice. Mice were sacrificed at 2 months
to examine tumor incidence via histopathology. Trans-
genic mice were maintained in accordance with the NIH
Guide for the Care and Use of Experimental Animals
with approval from our Institutional Animal Care and
Use Committee.
Immunohistochemical analyses
Mice were pulsed with BrdU (100 mg/kg) one hour prior
to sacrifice. Tissues were paraffin embedded and cut into
four micron sections. Sagittal sections were cut at mul-
tiple levels from each cerebellum analyzed and scored
for the presence or absence of tumor formation. Tissue
sections were stained with antibodies recognizing p27,
cyclin D1 and BrdU, and five high power fields (HPF)
were scored for each sample to quantify the proliferative
index within cerebellar tumors. Human medulloblastomatissues were stained with a monoclonal p27Kip1 antibo-
dy and detection carried out with 3,3’-diaminobenzidine
reagent. Tissue microarrays containing tissues from 87
patient samples were previously described [10]. P27 pro-
tein expression levels were also examined on tissue micro-
arrays containing tissues from 141 patients enrolled on
the SIOP PNET03 (1992–2000) study [11,12]. Staining
intensity was evaluated by observers blinded to patient
and survival data using the Nikon Elements Imagining
Software after slides were digitally scanned.
Statistics
For mouse studies, sagittal sections were cut at multiple
levels from each cerebellum analyzed to evaluate tumor
incidence and a Fisher’s exact test was used to determine
p values. A t test was used to determine p values for
quantification of the proliferative index. For human pa-
tients, overall survival was calculated from diagnosis
date until death or the last follow up date. Survival dis-
tribution was estimated by the Kaplan-Meier method
and compared using the log-rank test (SPSS 15.0). A
multivariate Cox proportional-hazards regression model,
with overall survival as the dependent variable, was used
to assess the impact of P27 expression levels on the three
individual components of the current risk stratification
model (metastasis, residual disease, age <3). Two-sided
p-values of less than 0.05 using the 95% confidential inter-
val were considered to indicate statistical significance.
Findings
Genetic alterations have been isolated from medulloblas-
tomas within signaling pathways that normally regulate
proliferation and differentiation of granule neuron pro-
genitors (GNPs) during cerebellar development [13]. Me-
dulloblastomas are induced in the SmoA1 mouse model
through the constitutive activation of the sonic hedgehog
(Shh) [GenBank: NM_009170] pathway within GNPs, sig-
naling normally required for GNP proliferation. p27Kip1
loss in mice can increase tumor formation [4], and p27Kip1
haploinsufficiency has been further supported by studies
using the Patched1 [GenBank: NM_008957] heterozy-
gous (Ptc1+/−) and SmoA1mouse medulloblastoma models
[5,14], where Shh-induced medulloblastoma incidence was
accelerated by loss of one or both p27Kip1 alleles.
To determine whether p27Kip1 loss affected medullo-
blastoma initiation or progression, we generated mice
hemizygous for the SmoA1 transgene that were hetero-
zygous (p27wt/-) or nullizygous for p27Kip1 (p27−/−) and
examined tumor incidence at two months of age, a time
point preceding symptomatic medulloblastoma onset.
Tumor incidence was 71.4% in SmoA1, p27wt/wt mice
(n = 35); 73.1% in SmoA1, p27wt/- mice (n = 52); and 60%
in SmoA1, p27−/− mice (n = 20). The differences were not
significant (p = 1.0 and p = 0.55, respectively). Tumors
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play significantly more invasive phenotypes (Figure 1).
60.5% of SmoA1, p27wt/- mice had invasive tumors and tu-
mors with effacement compared to 36.0% of SmoA1,
p27wt/wt mice (Figure 2A, p = 0.04). Similarly, 66.7% of
SmoA1, p27−/− mice displayed invasive and effaced path-
ology (Figure 2A, p = 0.08). The proliferative index, mea-
sured by bromodeoxyuridine (BrdU) incorporation, was
higher in tumors with invasive or effaced pathology and
greater in advanced tumors from SmoA1 mice lacking a
single or both p27Kip1 alleles than in tumors from SmoA1,
p27wt/wt mice (Figure 2B, p = 0.05 and p = 0.0001, respect-
ively). Increased tumor progression was associated with
decreased p27Kip1 and increased cyclinD1 [GenBank:
NM_009829] protein levels in tumors from both study
groups (Figure 2C-D).
An important observation can be drawn from compar-
ing tumor incidence at two months to the survival at
later time point results reported previously. Early tumor
formation was relatively unchanged by the loss of aFigure 1 Pathology criteria for SmoA1 tumor phenotype scoring. Sag
analyzed at the two-month time point and scored for the presence or abse
stained with a monoclonal cyclinD1 antibody to distinguish tumors (brown
stain). Additionally, tumors were scored as being non-invasive with no effa
criteria displayed in the panels above. Tumor pathology was graded by sev
effacement: tumors reside on the superficial surface of the molecular layer
Tumor margins are smooth and the IGL structure remains intact; (2) Invasiv
tumor invasion into the deeper region of the molecular layer. The IGL struc
cerebellum is encompassed in large dense sheets of tumor cells. Multi-foca
deeper region of the molecular layer, and disruption of IGL structure are cosingle or of both p27Kip1 alleles in our study. In contrast,
SmoA1 mice with wildtype p27Kip1 lived on average
twice as long as mice with a single copy of p27Kip1 [5],
and mice retaining wildtype p27Kip1 in the heterozygous
(Ptc1+/−) background survived significantly longer than
counterparts lacking p27Kip1, which succumbed due to
an increased tumor incidence [14]. In combination with
the aggressive pathology observed in early tumors from
SmoA1 mice lacking p27Kip1, the higher tumor incidence
in Ptc1+/− mice lacking p27Kip1 further confirms that
p27Kip1 is haploinsufficient in Shh-mediated medullo-
blastomas and that its loss of function contributes to
medulloblastoma progression.
We next assessed whether P27 levels could distinguish
children likely to fail therapy from those likely to be long-
term survivors. To properly evaluate P27 as a potential
marker of therapeutic response, we established quantita-
tive criteria for P27 staining in a training set of patient
samples then applied the same criteria to a larger test set.
Human medulloblastoma tissue microarrays containingittal sections were cut at multiple levels from each cerebellum
nce of tumor formation. Sections displayed in the panels have been
stain) from remaining normal cerebellum (blue Haematoxylin counter
cement, invasive with minimal effacement or effaced according the
erity into one of the following three groups: (1) Non-invasive with no
with a clearly established boundary between the IGL and the tumor.
e with minimal effacement: irregularly-shaped tumor margins with
ture remains intact; and (3) Effacement: a significant portion of the
l tumor formation with irregular tumor margins, invasion into the
mmonly noted.
Figure 2 Loss of p27Kip1 on the SmoA1 background facilitates tumor progression. (A) SmoA1, p27wt/- and SmoA1, p27−/− mice demonstrated
a significantly higher incidence of invasive and effaced tumors than SmoA1, p27wt/wt littermates. A Fisher’s exact test was used to generate p
values. (B) SmoA1, p27wt/- and SmoA1, p27−/− tumors demonstrated an increased proliferative index as determined by Bromodeoxyuridine (BrdU)
uptake. Cerebellar sections were stained with an antibody recognizing BrdU and five high power fields (HPF) were scored for each sample. Bars
represent the average number of BrdU positive cells per HPF, and error bars represent the standard error. A t test was used to determine p
values. (C-D) Immunohistochemistry with monoclonal antibodies recognizing p27Kip1 and cyclinD1 demonstrated that tumor progression is
associated with decreased p27Kip1 and increased cyclinD1 protein levels within tumors. Representative cerebellar sections from SmoA1, p27wt/-
cerebella showing p27Kip1 and cyclinD1 immunostaining in a non-invasive tumor with no effacement (NI/NE; C) and in a tumor with invasion and
effacement (I/E; D).
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expression [10]. 80% of samples evaluated had 20% or
fewer P27 positive cells, with 16% of samples having less
than 1% P27 positive cells. In contrast, intensity scoring of
control sections from normal human cerebella revealed an
average of 74% P27-positive granule cells (Figure 3A).
Additional P27 staining on individual human medulloblas-
toma sections from five patients revealed significant loss
of P27 protein (Figure 3B). Two tumor samples with re-
gions lacking P27 contained additional regions resemblingthe remaining normal cerebellar architecture that stained
positive for P27 (Figure 3C). Overall survival analysis
demonstrated that patients with very low P27 expression
had a poor outcome. Significant correlations were found
when patients were stratified between high and low P27
levels, with patients with higher P27 levels (>1% P27 posi-
tive cells) having a more favorable outcome (n = 79,
p = 0.027, data not shown). This correlation persisted
when patients were additionally stratified by factors that
define the standard-risk subgroup. P27 expression had
Figure 3 P27 loss is a feature common in human medulloblastomas. Human tumor tissue was obtained from the brain tumor tissue bank at
Children’s Hospital in Seattle. These studies had prior approval from the Institutional Review Board and informed consent was obtained for all
samples. Control brain samples were from four pediatric subjects (median age 16 yr, range 11-18 yrs) who died from trauma or non-malignant
disease. These were from the Maryland Brain Bank, supplied by the laboratory of Dr. Gregory Riggins. (A) Representative P27 staining in the
human cerebellum from a pediatric patient that died of non-cancer-related trauma demonstrates P27 expression in over 70% of granule cells. (B-
C) Sections from human medulloblastoma samples were stained for P27, with panel (B) representative of the observed P27 protein loss within
tumors. (C) Granule neurons within the remaining normal cerebellar architecture from the tumor sample shown in panel (B) exhibit strong,
nuclear P27 staining. (D) Kaplan-Meier analysis from the second study of 141 patients enrolled on the SIOP PNET3 study [11,12]. Patients were
grouped into three categories: N, with virtually no (<1%) P27-positive cells (n = 2), F, with less than 10% P27-positive cells and M, with greater
than 10% P27-positive cells. Patients from groups F and N were grouped together because they represented only 13 of the 141 patients
examined. Because desmoplastic/nodular tumors have a heterogeneous P27 staining pattern with pockets of strong P27 expression among fields
of low or variable staining, we analyzed the test data set including and excluding patients with desmoplastic/nodular tumors, but neither analysis
revealed prognostic value for P27.
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with total surgical resection (n = 30, p = 0.001) or a lack of
metastasis (n = 44, p = 0.007). While the number of pa-
tients with clinical data for all three standard-risk parame-
ters was too small for Kaplan-Meier analysis, multivariate
analysis with overall survival as the dependent variable
demonstrated that P27 expression levels had prognostic
value, independent of the extent of tumor resection or
metastasis.
Together, these data suggested that P27 absence could
further stratify standard-risk patients between survivors
and those that fail therapy and do not survive. Because
incorrect patient stratification could result in death for
children placed improperly into a lower risk group, or
unnecessary toxicity in children placed improperly into a
higher risk group, we sought to confirm these findings
by examining tissues from a second, larger study popu-
lation. Tissues from 141 patient samples from childrentreated on the SIOP PNET03 clinical trial in Europe
were stained for P27 and analyzed as above [11,12]. Only
two patients were identified that met the <1% cutoff cri-
teria, indicating that the threshold established in the
training set was not suitable for the test data set. To de-
termine if this threshold was too stringent, we relaxed
the criteria to <10% to capture more patients with low
P27 expression. No significant differences were found in
overall survival (P = 0.67) or in progression free survival
(P = 0.55) between patients with little to no (less than
10%, F/N) P27 cells and those with greater than 10%
P27 positive cells (M) (Figure 3D). We therefore con-
clude that the first test set was a false positive signal,
likely due to small numbers and retrospective establish-
ment of the cutoff criteria. This discrepancy underscores
the importance of evaluating potential prognostic indica-
tors in large patient populations and using both training
and test data sets when developing candidate prognostic
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first quantitative analysis of P27 expression in a large co-
hort of human medulloblastoma samples.
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